Related Experiment Video
Updated: Dec 28, 2025

A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro
Published on: June 2, 2022
The predictive value of serum galectin 3 for abdominal aortic calcification in maintenance hemodialysis patients: A
Zhiyu Wang1, Zijin Chen1, Xiaobo Ma1
1Division of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Insights
Serum Galectin-3 (Gal-3) shows significant predictive value for severe abdominal aortic calcification (AAC) and its progression in patients undergoing maintenance hemodialysis (MHD). This finding suggests Gal-3 may serve as a key biomarker for vascular calcification in ESRD patients.
Area of Science:
- Nephrology
- Cardiovascular Medicine
- Biomarker Discovery
Background:
- Heterotopic vascular calcification is a frequent complication in maintenance hemodialysis (MHD) patients.
- Galectin-3 (Gal-3) has been linked to cardiovascular calcification, prompting investigation into its role in MHD patients.
Purpose of the Study:
- To investigate the predictive value of serum Gal-3 for severe abdominal aortic calcification (AAC) and AAC progression.
- To assess Gal-3 as a potential biomarker for vascular calcification in end-stage renal disease (ESRD) patients on MHD.
Main Methods:
- A prospective cohort study followed 152 MHD patients for 3 years with two AAC assessments.
- Serum Gal-3 levels were measured using quantitative ELISA kits.
- Statistical analysis included logistic regression and ROC curve analysis.
Main Results:
- Serum Gal-3 was identified as an independent risk factor for severe AAC and AAC progression.
- ROC curve analysis confirmed the significant prognostic value of serum Gal-3 for predicting severe AAC and its progression within 3 years.
Conclusions:
- Serum Gal-3 is correlated with vascular calcification in ESRD patients.
- Gal-3 may serve as a potential biomarker for vascular calcification in MHD patients.
Introduction:
Heterotopic vascular calcification is a common complication of maintenance hemodialysis (MHD) patients. Galectin 3 (Gal-3) has been reported to be associated with cardiovascular calcification. The current study aims to explore the potential predictive value of serum Gal-3 for severe abdominal aortic calcification (AAC) and AAC progression in MHD patients.
Methods:
A prospective cohort who underwent hemodialysis during July 2014 at the Blood Purification Center of Ruijin Hospital were followed up for 3 years. Two AAC assessments were performed: one at baseline and one after the 3-year follow-up period. Serum Gal-3 was detected with quantitative ELISA kits. SPSS 23.0 and MedCalc 11.4.2.0 were used to analyze the data.
Findings:
One hundred and fifty-two patients were recruited. Approximately 59.9% were male, the median age was 60 (50-67) years. Logistic regression analysis indicated that serum Gal-3 was an independent risk factor for both follow-up severe AAC and AAC progression. Receiver operating characteristic (ROC) curve analysis revealed significant prognostic value of serum Gal-3 for predicting severe AAC and AAC progression within 3 years.
Discussion:
We found serum Gal-3 is correlated to vascular calcification in ESRD patients. Gal-3 may be a potential biomarker of vascular calcification for MHD patients.
Related Concept Videos
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

